Patent Grant
11944315
The present invention generally relates to an occlusion device for occluding a left atrial appendage.
The left atrial appendage (LAA) is a cavity that presents in the left atrium of the heart. In patients with atrial fibrillation, the passage and steadiness of blood within this cavity can cause thrombus formation, which increases the risk of stroke. Percutaneous LAA occlusion is a therapy for the prevention of stroke in patients with atrial fibrillation. LAA occlusion is used as an alternative to, or in combination with, oral anticoagulant therapy. LAA occlusion has favorable clinical outcomes, but commercially-available devices are typically self-expandable, and not designed to adapt to the LAA anatomy, and thus sometimes result in complications or suboptimal outcomes. In these environments, some of the currently available occlusion devices are limited by the poor adaptability of the device to the defect (lack of conformability) and by a lack of intra-device sealing (due to the high-flow environment).
PCT Publication WO 2019/057950 to Maisano et al. describes an occluder device for occluding a cardiovascular defect or a gap between a medical device and adjacent body tissue, including a compliant balloon defining a fluid-tight balloon chamber and provided with a balloon channel forming a longitudinal passage from a proximal side to a distal side of the balloon; a tip element disposed at the distal side of the balloon, a base element disposed at the proximal side of the balloon, and connecting means comprising at least one connecting strut attached to the tip element and to the base element, the tip element and the base element each having a guide opening substantially coaxial to the balloon channel for slidingly receiving therein a guidewire for the device; elongated actuating means disposed longitudinally slidable in the balloon channel, releasably connectable to the tip element, and longitudinally slidable with respect to the base element; locking means for maintaining a predetermined distance between the tip element and the base element; and proximal connector means for releasably connecting the occluder device to correspondingly configured distal connector means of a catheter device. The balloon includes a fluid port for filling and unfitting a fluid into and from the balloon chamber. An occluder system comprises an occluder device and a catheter device cooperating therewith.
U.S. Pat. No. 6,652,556 to VanTassel et al. describes apparatus for permanent placement across an ostium of a left atrial appendage in a patient, which includes a filtering membrane configured to extend across the ostium of the left atrial appendage. The filtering membrane has a permeable structure which allows blood to flow through but substantially inhibits thrombus from passing therethrough. The apparatus also includes a support structure comprising a plurality of fingers which are radially outwardly expandable with respect to a longitudinal axis to permanently engage the interior wall of the left atrial appendage. The filtering membrane is attached to the support structure extending across the ostium of the left atrial appendage.
Some embodiments of the present invention provide occlusion devices for mechanically occluding a left atrial appendage (LAA). The occlusion devices comprise a compliant balloon defining a fluid-tight balloon chamber, and an actuating shaft, which is (a) disposed at least partially within the balloon chamber, (b) connected to a distal end portion of the balloon, and (c) longitudinally moveable with respect to a proximal end portion of the balloon so as to set a distance between the distal and the proximal end portions of the balloon. The occlusion devices also comprise a valve, which can be closed after inflation of the balloon chamber.
The shape and compliancy of the occlusion devices, optionally including plastic deformation of struts thereof, enable anchoring of the occlusion devices and sealing of the LAA while allowing for conformation and adaptation to the geometrical attributes of the LAA, thereby filling the space of the LAA at least to a certain extent, regardless of the particular morphological type of the LAA.
In addition, delivery systems are provided that enable over-the-wire engagement to the LAA, the adjustment of the length and orientation of the occlusion devices during deployment, and the inflation of the balloon chamber with saline or another filling liquid.
The occlusion devices described herein are designed to be delivered into the LAA while longitudinally extended, and either entirely or partially compressed. After delivery, the occlusion devices are adapted to the landing zone anatomy by inflating the balloon chamber and shortening the longitudinal dimension of struts arranged between proximal and distal end portions of the balloon. Under the influence of internal pressure from inflation, the balloon chamber assumes a certain volume which, for a given longitudinal balloon dimension, results in a certain lateral or radial dimension, which provides a good seal between the balloon and the adjacent anatomy of the LAA. Changing the longitudinal balloon dimension, by selecting a different distance between the distal and proximal end portions of the balloon, results in a corresponding change in the radial or lateral extension of the balloon. In other words, shortening the distance between the distal and proximal end portions of the balloon results in a corresponding increase in radial or lateral extension under otherwise constant conditions, which improves the seal with the adjacent tissue of the LAA and inhibits unwanted blood passage. The lateral extension of the balloon is not necessarily symmetric, either because the balloon is not necessarily symmetric and/or because the anatomy against which the balloon is laterally expanded may cause asymmetric balloon expansion. The radial or lateral expansion together include within their scope one or more directions generally perpendicular to the longitudinal axis of the balloon.
In the context of the present disclosure, the terms “distal” and “proximal” are used accordingly to their standard meaning in the field of percutaneous cardiovascular devices. The term “proximal” refers to those components of the device assembly which, when following a delivery catheter during percutaneous delivery, are closer to the end of the catheter that is configured for manipulation by the user (e.g., a catheter handle manipulated by a physician). The term “distal” is used to refer to those components of the device assembly that are more distant from the end of the catheter that is configured for manipulation by the user and/or that are inserted farther into the body of a patient.
The term “compliant” used herein in relation with balloons or with structural components implies a deformability that substantially follows an applied force. Accordingly, a “compliant balloon” means a balloon which progressively expands under the effect of increasing radial pressure as long as a certain burst pressure is not exceeded.
As used herein, the term “strut” means an elongate structural element which can be formed, e.g., a thin wire, rod, or thick-walled tube, all of which do not necessarily have a circular cross section.
There is therefore provided, in accordance with an Inventive Concept 1 of the present invention, an occlusion device for occluding a left atrial appendage (LAA), the occlusion device for use with a delivery system, the occlusion device including:
a compliant balloon defining a fluid-tight balloon chamber;
an actuating shaft, which is (a) disposed at least partially within the balloon chamber, (b) connected to a distal end portion of the balloon, and (c) longitudinally moveable with respect to a proximal end portion of the balloon so as to set a distance between the distal and the proximal end portions of the balloon;
a proximal LAA-orifice cover, which (a) is configured to assume a radially-compressed state and a radially-expanded state, (b) includes a frame and a covering fixed to the frame, and (c) when in the radially-expanded state, is generally orthogonal to the actuating shaft and has a greatest dimension, measured perpendicular to the actuating shaft, of between 10 and 50 mm; and
an orifice-support stent, which (a) is fixed to and extends distally from the proximal LAA-orifice cover, (b) is configured to assume a radially-compressed state and a radially-expanded state, and (c) is generally cylindrical when in the radially-expanded state.
Inventive Concept 2. The occlusion device according to Inventive Concept 1, wherein the orifice-support stent, when in the radially-expanded state, has (i) a greatest dimension, measured perpendicular to the actuating shaft, of between 8 and 50 mm, and (ii) an axial length of between 4 and 30 mm.
Inventive Concept 3. The occlusion device according to Inventive Concept 1, wherein the occlusion device further includes a distal tip disposed at the distal end portion of the balloon, wherein the actuating shaft is connected to the distal tip.
Inventive Concept 4. The occlusion device according to Inventive Concept 1, wherein the actuating shaft is shaped so as to define, at least in part, a distal tip disposed at the distal end portion of the balloon.
Inventive Concept 5. The occlusion device according to Inventive Concept 1, wherein the occlusion device further includes a proximal base disposed at the proximal end portion of the balloon, wherein the actuating shaft is moveable with respect to the proximal base.
Inventive Concept 6. The occlusion device according to Inventive Concept 1, for use with a guidewire, wherein the actuating shaft is shaped so as to define a guidewire lumen for slidingly receiving therein the guidewire.
Inventive Concept 7. The occlusion device according to Inventive Concept 1, wherein the compliant balloon includes a compliant material selected from the group consisting of: polycaprolactone (PCL), polyglycolic acid (PGA), polylactic acid (PLA), and polydioxanone (PDO or PDS), silicone, polyurethane, polytetrafluoroethylene (PTFE), polymethylmethacrylate, polyether ether ketone (PEEK), polyvinyl chloride, polyethylene terephthalate, nylon, polyamide, polyamide, and polyether block amide (PEBA).
Inventive Concept 8. The occlusion device according to any one of Inventive Concepts 1-7, wherein the orifice-support stent is not fixed to the balloon, such that a shape of the balloon can change independently of a shape of the orifice-support stent.
Inventive Concept 9. The occlusion device according to any one of Inventive Concepts 1-7, wherein the occlusion device is configured such that inflation of the balloon chamber transitions the orifice-support stent from its radially-compressed state to its radially-expanded state.
Inventive Concept 10. The occlusion device according to any one of Inventive Concepts 1-7,
wherein the occlusion device further includes a proximal tube, which is axially fixed with respect to the proximal end portion of the balloon, and
wherein the proximal LAA-orifice cover is fixed to the proximal tube radially surrounding the proximal tube, and is indirectly connected to the balloon via the proximal tube and is not directly connected to the balloon.
Inventive Concept 11. The occlusion device according to Inventive Concept 10, wherein the actuating shaft is slidably disposed partially within the proximal tube.
Inventive Concept 12. The occlusion device according to any one of Inventive Concepts 1-7, wherein the occlusion device further includes connecting struts fixed to the distal end portion of the balloon and to the proximal end portion of the balloon.
Inventive Concept 13. The occlusion device according to Inventive Concept 12, wherein the occlusion device is configured such that inflation of the balloon chamber plastically deforms the connecting struts.
Inventive Concept 14. The occlusion device according to Inventive Concept 12, wherein the occlusion device is configured such that shortening of the balloon plastically deforms the connecting struts.
Inventive Concept 15. The occlusion device according to any one of Inventive Concepts 1-7, wherein the balloon has an average wall thickness of between 100 and 5000 microns.
Inventive Concept 16. The occlusion device according to any one of Inventive Concepts 1-7, wherein the balloon has, at a thinnest portion of a wall of the balloon, a thinnest wall thickness of between 20 and 500 microns.
Inventive Concept 17. An occlusion system including the occlusion device according to any one of Inventive Concepts 1-7, the occlusion system further including an implant catheter, in which the occlusion device is releasably disposed in a radially-compressed state, in which a greatest distance between the proximal end portion of the balloon and the distal end portion of the balloon is between 8 and 80 mm.
Inventive Concept 18. The occlusion device according to any one of Inventive Concepts 1-7, further including a valve.
Inventive Concept 19. The occlusion device according to Inventive Concept 18,
wherein the occlusion device is shaped so as to define a fluid flow path, and
wherein the valve is configured to selectively allow or block fluid flow between the fluid flow path and the balloon chamber when the valve is in open and closed states, respectively.
Inventive Concept 20. The occlusion device according to Inventive Concept 19,
wherein the occlusion device is shaped so as to define the fluid flow path along a portion of the actuating shaft,
wherein the occlusion device further includes a locking mechanism, which is configured to assume locked and unlocked states, and which is configured, when in the locked state, to maintain, between the distal end portion of the balloon and the proximal end portion of the balloon, the distance set using the actuating shaft, and
wherein the occlusion device is configured such that reduction of the distance, by proximal longitudinal movement of the actuating shaft:
There is further provided, in accordance with an Inventive Concept 25 of the present invention, an occlusion device for occluding a left atrial appendage (LAA), the occlusion device for use with a delivery system, the occlusion device including:
There is still further provided, in accordance with an Inventive Concept 57 of the present invention, an occlusion device for occluding a left atrial appendage (LAA), the occlusion device for use with a delivery system, the occlusion device including:
a compliant balloon defining a fluid-tight balloon chamber;
an actuating shaft, which is (a) disposed at least partially within the balloon chamber, (b) connected to a distal end portion of the balloon, and (c) longitudinally moveable with respect to a proximal end portion of the balloon so as to set a distance between the distal and the proximal end portions of the balloon; and
connecting struts fixed to the distal end portion of the balloon and to the proximal end portion of the balloon, wherein the connecting struts include:
wherein the distal interface portions are shaped so as to define respective pairs of parallel serpentine struts that define respective narrow elongate gaps therebetween, and
wherein the struts are shaped so as to define a plurality of spikes, which:
There is additionally provided, in accordance with an Inventive Concept 72 of the present invention, an occlusion device for occluding a left atrial appendage (LAA), the occlusion device for use with a delivery system, the occlusion device including:
a compliant balloon defining a fluid-tight balloon chamber;
an actuating shaft, which is (a) disposed at least partially within the balloon chamber, (b) connected to a distal end portion of the balloon, and (c) longitudinally moveable with respect to a proximal end portion of the balloon so as to set a distance between the distal and the proximal end portions of the balloon; and
connecting struts fixed to the distal end portion of the balloon and to the proximal end portion of the balloon, wherein the connecting struts include:
wherein the distal interface portions are shaped so as to define respective pairs of parallel serpentine struts that define respective narrow elongate gaps therebetween, and
wherein the struts are shaped so as to define a plurality of spikes, which:
There is yet additionally provided, in accordance with an Inventive Concept 87 of the present invention, an occlusion device for occluding a left atrial appendage (LAA), the occlusion device for use with a delivery system, the occlusion device including:
a compliant balloon defining a fluid-tight balloon chamber;
an actuating shaft, which is (a) disposed at least partially within the balloon chamber, (b) connected to a distal end portion of the balloon, and (c) longitudinally moveable with respect to a proximal end portion of the balloon so as to set a distance between the distal and the proximal end portions of the balloon; and
connecting struts fixed to the distal end portion of the balloon and to the proximal end portion of the balloon, wherein the connecting struts include:
There is also provided, in accordance with an Inventive Concept 92 of the present invention, a method for occluding a left atrial appendage (LAA) of a patient, the method including:
using a delivery system, positioning:
inflating the compliant balloon by filling, via a fluid flow path along a portion of the actuating shaft, a fluid into the balloon chamber;
expanding the balloon in a radial or a lateral direction by shortening the distance between the distal and the proximal end portions of the balloon to a desired distance; and
releasing the occlusion device from the delivery system.
Inventive Concept 93. The method according to Inventive Concept 92, wherein the orifice-support stent is not fixed to the balloon, such that a shape of the balloon can change independently of a shape of the orifice-support stent.
Inventive Concept 94. The method according to Inventive Concept 92, wherein inflating the compliant balloon transitions the orifice-support stent from its radially-compressed state to its radially-expanded state.
There is further provided, in accordance with an Inventive Concept 95 of the present invention, a method for occluding a left atrial appendage (LAA) of a patient, the method including:
using a delivery system, positioning a compliant balloon of an occlusion device in a longitudinally extended form thereof in the LAA;
inflating the compliant balloon by filling, via a fluid flow path along a portion of an actuating shaft of the occlusion device, a fluid into a fluid-tight balloon chamber defined by the balloon, while a valve of the occlusion device in an open state in which the valve allows fluid flow between the fluid flow path and the balloon chamber, wherein the actuating shaft is (a) disposed at least partially within the balloon chamber, (b) connected to a distal end portion of the balloon, and (c) longitudinally moveable with respect to a proximal end portion of the balloon so as to set a distance between the distal and the proximal end portions of the balloon;
expanding the balloon in a radial or a lateral direction by shortening the distance between the distal and the proximal end portions of the balloon to a desired distance, by proximally longitudinally moving the actuating shaft:
advancing a guidewire into a body of the patient using the delivery system; and
advancing the occlusion device over the guidewire.
Inventive Concept 97. The method according to Inventive Concept 95, wherein the first predetermined distance does not equal the second predetermined distance.
Inventive Concept 98. The method according to Inventive Concept 97, wherein the first predetermined distance is less than the second predetermined distance.
Inventive Concept 99. The method according to Inventive Concept 95, wherein the first predetermined distance equals the second predetermined distance.
Inventive Concept 100. The method according to Inventive Concept 95, wherein the occlusion device is shaped so as to define the fluid flow path alongside the portion of the actuating shaft.
Inventive Concept 101. The method according to Inventive Concept 95, wherein the valve is disposed along the actuating shaft.
Inventive Concept 102. The method according to Inventive Concept 95, wherein the occlusion device further includes a proximal tube, which is axially fixed with respect to the proximal end portion of the balloon, wherein the actuating shaft is slidably disposed partially within the proximal tube.
Inventive Concept 103. The method according to Inventive Concept 102, wherein the occlusion device is shaped so as to define the fluid flow path along the portion of the actuating shaft radially between an external surface of the actuating shaft and an internal surface of the proximal tube.
Inventive Concept 104. The method according to Inventive Concept 103, wherein the valve is disposed along the actuating shaft.
Inventive Concept 105. The method according to Inventive Concept 104, wherein the valve includes a seal around at least a portion of the external surface of the actuating shaft, and wherein the valve is configured to assume the open state when the seal is disposed at one or more first axial positions with respect to the proximal tube, and the closed state when the seal is disposed at one or more second axial positions with respect to the proximal tube, the one or more second axial positions proximal to the one or more first axial positions.
Inventive Concept 106. The method according to Inventive Concept 105, wherein the seal, the actuating shaft, and the proximal tube are arranged such that the seal blocks fluid flow out of a distal end of the proximal tube at least when the seal is disposed at the one or more first axial positions with respect to the proximal tube.
Inventive Concept 107. The method according to Inventive Concept 103, wherein a wall of the proximal tube is shaped so as to define one or more tabs through the wall, wherein the one or more tabs are biased to flex radially inward, and wherein, when the valve is in the open state, the fluid flow path passes through the wall between respective proximal ends of the one or more tabs and a non-tabbed portion of the wall axially adjacent the one or more tabs.
Inventive Concept 108. The method according to Inventive Concept 107, wherein the non-tabbed portion of the wall is disposed proximal to the one or more tabs.
Inventive Concept 109. The method according to Inventive Concept 107, wherein the external surface of the actuating shaft is shaped so as to define one or more protrusions around at least a portion of the actuating shaft, and wherein the proximal ends of the one or more tabs are shaped so as to prevent distal movement of the one or more protrusions when the one or more protrusions are disposed proximal to the proximal ends of the one or more tabs, thereby causing the locking mechanism to assume the locked state.
Inventive Concept 110. The method according to Inventive Concept 102, wherein the occlusion device further includes a proximal LAA-orifice cover, which (a) is fixed to the proximal tube radially surrounding the proximal tube, (b) is configured to assume a radially-compressed state and a radially-expanded state, (c) includes a frame and a covering fixed to the frame, (d) when in the radially-expanded state, is generally orthogonal to the proximal tube and has a greatest dimension, measured perpendicular to the proximal tube, of between 10 and 50 mm, and (e) is indirectly connected to the balloon via the proximal tube and is not directly connected to the balloon.
Inventive Concept 111. The method according to Inventive Concept 110, wherein the occlusion device further includes an orifice-support stent, which (a) is fixed to and extends distally from the proximal LAA-orifice cover, (b) is configured to assume a radially-compressed state and a radially-expanded state, and (c) is generally cylindrical when in the radially-expanded state.
Inventive Concept 112. The method according to Inventive Concept 111, wherein the orifice-support stent, when in the radially-expanded state, has (i) a greatest dimension, measured perpendicular to the actuating shaft, of between 8 and 50 mm, and (ii) an axial length of between 4 and 30 mm.
Inventive Concept 113. The method according to Inventive Concept 95, wherein the occlusion device further includes connecting struts fixed to the distal end portion of the balloon and to the proximal end portion of the balloon.
Inventive Concept 114. The method according to Inventive Concept 113, wherein the occlusion device is configured such that inflation of the balloon chamber plastically deforms the connecting struts.
Inventive Concept 115. The method according to Inventive Concept 113, wherein the occlusion device is configured such that shortening of the balloon plastically deforms the connecting struts.
There is still further provided, in accordance with an Inventive Concept 116 of the present invention, apparatus for occluding a left atrial appendage (LAA), the apparatus including:
(i) an occlusion device, including:
(ii) a delivery system, which is configured to be releasably connected to the occlusion device, and which includes a valve-opening prop, which is configured:
There is additionally provided, in accordance with an Inventive Concept 144 of the present invention, apparatus for occluding a left atrial appendage (LAA), the apparatus including:
(i) an occlusion device, including:
(ii) a delivery system, which is configured to be releasably connected to the occlusion device, and which includes one or more guidewires, which:
There is yet additionally provided, in accordance with an Inventive Concept 151 of the present invention, apparatus for occluding a left atrial appendage (LAA), the apparatus including:
(i) an occlusion device, including:
(ii) a delivery system, which is configured to be releasably connected to the occlusion device, and which includes a stylet, which is removably disposed through the proximal tube and within the spring, wherein the occlusion device is configured such that a degree of distal advancement of the stylet within the spring sets a tensed length of the spring, which in turn sets a tensed distance between the distal and the proximal end portions of the balloon, the tensed distance greater than the relaxed distance.
Inventive Concept 152. The apparatus according to Inventive Concept 151, wherein the occlusion device further includes a valve.
Inventive Concept 153. The apparatus according to Inventive Concept 152,
wherein the occlusion device is shaped so as to define a fluid flow path, and
wherein the valve is configured to selectively allow or block fluid flow between the fluid flow path and the balloon chamber when the valve is in open and closed states, respectively.
Inventive Concept 154. The apparatus according to Inventive Concept 151, wherein the occlusion device further includes a distal tip disposed at the distal end portion of the balloon, wherein the spring is connected to the distal tip.
Inventive Concept 155. The apparatus according to Inventive Concept 151, wherein the compliant balloon includes a compliant material selected from the group consisting of: polycaprolactone (PCL), polyglycolic acid (PGA), polylactic acid (PLA), and polydioxanone (PDO or PDS), silicone, polyurethane, polytetrafluoroethylene (PTFE), polymethylmethacrylate, polyether ether ketone (PEEK), polyvinyl chloride, polyethylene terephthalate, nylon, polyamide, polyamide, and polyether block amide (PEBA).
Inventive Concept 156. The apparatus according to any one of Inventive Concepts 151-155,
wherein the occlusion device includes an occlusion-device connector, which is connected to the distal end portion of the balloon and is shaped so as to define an occlusion-device connection interface, and
wherein the stylet includes a stylet connector, which is disposed at a distal end of the stylet and is shaped so as to define a stylet connection interface that is reversibly couplable to the occlusion-device connection interface.
Inventive Concept 157. The apparatus according to Inventive Concept 156, wherein the occlusion-device connection interface and the stylet connection interface are shaped so as to define respective threads.
Inventive Concept 158. The apparatus according to any one of Inventive Concepts 151-155, wherein the occlusion device further includes a proximal LAA-orifice cover, which (a) is fixed to the proximal tube radially surrounding the proximal tube, (b) is configured to assume a radially-compressed state and a radially-expanded state, (c) includes a frame and a covering fixed to the frame, (d) when in the radially-expanded state, is generally orthogonal to the proximal tube and has a greatest dimension, measured perpendicular to the proximal tube, of between 10 and 50 mm, and (e) is indirectly connected to the balloon via the proximal tube and is not directly connected to the balloon.
Inventive Concept 159. The apparatus according to Inventive Concept 158, wherein the occlusion device further includes an orifice-support stent, which (a) is fixed to and extends distally from the proximal LAA-orifice cover, (b) is configured to assume a radially-compressed state and a radially-expanded state, and (c) is generally cylindrical when in the radially-expanded state.
Inventive Concept 160. The apparatus according to Inventive Concept 159, wherein the orifice-support stent, when in the radially-expanded state, has (i) a greatest dimension, measured perpendicular to the proximal tube, of between 8 and 50 mm, and (ii) an axial length of between 4 and 30 mm.
Inventive Concept 161. The apparatus according to any one of Inventive Concepts 151-155, wherein the occlusion device further includes connecting struts fixed to the distal end portion of the balloon and to the proximal end portion of the balloon.
Inventive Concept 162. The apparatus according to Inventive Concept 161, wherein the occlusion device is configured such that inflation of the balloon chamber plastically deforms the connecting struts.
Inventive Concept 163. The apparatus according to Inventive Concept 161, wherein the occlusion device is configured such that shortening of the balloon plastically deforms the connecting struts.
Inventive Concept 164. The apparatus according to any one of Inventive Concepts 151-155, wherein the balloon has an average wall thickness of between 100 and 5000 microns.
Inventive Concept 165. The apparatus according to any one of Inventive Concepts 151-155, wherein the balloon has, at a thinnest portion of a wall of the balloon, a thinnest wall thickness of between 20 and 500 microns.
Inventive Concept 166. The apparatus according to any one of Inventive Concepts 151-155, wherein the delivery system further includes an implant catheter, in which the occlusion device is releasably disposed in a radially-compressed state, in which a greatest distance between the proximal end portion of the balloon and the distal end portion of the balloon is between 8 and 80 mm.
Inventive Concept 167. The apparatus according to Inventive Concept 151, wherein the occlusion device further includes a proximal connector that is configured to releasably connect the occlusion device to a correspondingly configured distal connector of the delivery system.
Inventive Concept 168. The apparatus according to Inventive Concept 167, wherein the proximal connector is shaped so as to define a thread.
Inventive Concept 169. The apparatus according to any one of Inventive Concepts 167-168, for use with a guidewire, wherein the delivery system further includes an implant catheter connected to an operating handle, the implant catheter including a longitudinal passageway for the guidewire, a distal connector for releasably connecting the implant catheter to the correspondingly configured proximal connector of the occlusion device, and an inflation tube channel releasably connectable to the fluid flow path of the occlusion device.
There is also provided, in accordance with an Inventive Concept 170 of the present invention, a method for occluding a left atrial appendage (LAA) of a patient, the method including:
using a delivery system, positioning a compliant balloon of an occlusion device in a longitudinally extended form thereof in the LAA;
inflating the compliant balloon by filling a fluid into a fluid-tight balloon chamber defined by the balloon, via a fluid flow path having one or more fluid-flow-path openings to the balloon chamber, while a valve-opening prop of the delivery system is in a propping position in which the valve-opening prop props open and deforms an elastomer sleeve of a valve of the occlusion device, such that the elastomer sleeve does not seal the one or more fluid-flow-path openings and the valve is in an open state, wherein the elastomer sleeve surrounds a portion of an actuating shaft of the occlusion device, the actuating shaft (a) disposed at least partially within the balloon chamber, (b) connected to a distal end portion of the balloon, and (c) longitudinally moveable with respect to a proximal end portion of the balloon so as to set a distance between the distal and the proximal end portions of the balloon;
transitioning the valve-opening prop to a non-propping position, in which the valve-opening prop does not prop open the elastomer sleeve, such that elastomer sleeve assumes a resting state in which the sleeve covers and seals the one or more fluid-flow-path openings, such that the valve is in a closed state; and
releasing the occlusion device from the delivery system.
There is further provided, in accordance with an Inventive Concept 171 of the present invention, a method for occluding a left atrial appendage (LAA) of a patient, the method including:
using a delivery system, positioning a compliant balloon of an occlusion device in a longitudinally extended form thereof in the LAA;
inflating the compliant balloon by filling a fluid into a fluid-tight balloon chamber defined by the balloon, via a fluid flow path having one or more fluid-flow-path openings to the balloon chamber, while one or more guidewires of the delivery system are in a propping position, in which the one or more guidewires prop open and deform an elastomer sleeve of a valve of the occlusion device such that the elastomer sleeve does not seal the one or more fluid-flow-path openings and the valve is in an open state, wherein the elastomer sleeve surrounds a portion of an actuating shaft that is (a) disposed at least partially within the balloon chamber, (b) connected to a distal end portion of the balloon, and (c) longitudinally moveable with respect to a proximal end portion of the balloon so as to set a distance between the distal and the proximal end portions of the balloon;
transitioning the one or more guidewires to a non-propping position, in which the one or more guidewires do not prop open the elastomer sleeve, such that elastomer sleeve assumes a resting state in which the sleeve covers and seals the one or more fluid-flow-path openings, such that the valve is in a closed state; and
releasing the occlusion device from the delivery system.
The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings, in which:
Reference is also made to
For some applications, occlusion device 10 comprises:
Occlusion device 10 is configured such that proximally longitudinally moving actuating shaft 34 expands balloon 30 in a radial or a lateral direction by shortening the distance between distal and proximal end portions 36 and 38 of balloon 30 to a desired distance.
Locking mechanism 40 is configured, when in the locked state, to maintain, between distal end portion 36 of balloon 30 and proximal end portion 38 of balloon 30, the distance set using actuating shaft 34.
For some applications, occlusion device 10 is shaped so as to define a fluid flow path 44 along (e.g., alongside, as shown) a portion of actuating shaft 34. Valve 42 is configured to selectively:
For some applications, occlusion device 10 is configured such that reduction of the distance, by proximal longitudinal movement of actuating shaft 34:
For some applications, the first predetermined distance does not equal the second predetermined distance. For example, the first predetermined distance may be less than the second predetermined distance, such that the proximal longitudinal movement of actuating shaft 34 first automatically transitions valve 42 from the open state to the closed state and subsequently automatically transitions locking mechanism 40 from the unlocked state to the locked state. Alternatively, the first predetermined distance may be greater than the second predetermined distance, such that this sequence is reversed.
Further alternatively, for some applications, the first predetermined distance equals the second predetermined distance, such that the proximal longitudinal movement of actuating shaft 34 simultaneously automatically transitions valve 42 from the open state to the closed state and automatically transitions locking mechanism 40 from the unlocked state to the locked state.
For some applications, in order to cause the above-mentioned proximal longitudinal movement of actuating shaft 34, delivery system 20 comprises a pull shaft 46, which is releasably coupled a proximal end portion of actuating shaft 34. For example, a distal portion of pull shaft 46 may comprise a pull-shaft coupling 48, which may, for example, be shaped so as to define a thread that removably engages a corresponding thread defined by the proximal end portion of actuating shaft 34. Rotation of pull shaft 46 disengages shaft coupling 48 from the corresponding thread defined by the proximal end portion of actuating shaft 34.
Typically, occlusion device 10 is configured to be releasably connected to delivery system 20. For some applications, occlusion device 10 is configured such that fluid flow path 44 is coupled in fluid communication with delivery system 20 when occlusion device 10 is releasably connected to delivery system 20, such as shown in
For some applications, actuating shaft 34 is shaped so as to define, at least in part, a distal tip 50 disposed at distal end portion 36 of balloon 30, as shown in
For some other applications, occlusion device 10 further comprises a distal tip disposed at distal end portion 36 of balloon 30, and actuating shaft 34 is connected to the distal tip (configuration not shown).
Alternatively or additionally, for some applications, occlusion device 10 further comprises a proximal base disposed at proximal end portion 38 of balloon 30, and actuating shaft 34 is moveable (e.g., longitudinally or rotationally) with respect to the proximal base (configuration not shown).
For some applications, valve 42 is disposed along actuating shaft 34, such as shown in
For some applications, occlusion device 10 further comprises a proximal tube 52, which is axially fixed with respect to proximal end portion 38 of balloon 30. Actuating shaft 34 is slidably disposed partially within proximal tube 52, e.g., so as to indirectly connect actuating shaft 34 to proximal end portion 38 via proximal tube 52. For some of these applications, occlusion device 10 is shaped so as to define fluid flow path 44 along the portion of actuating shaft 34, radially between an external surface of actuating shaft 34 and an internal surface of proximal tube 52, such as shown in
For some applications, valve 42 comprises a seal 54 around at least a portion of (e.g., entirely around) the external surface of actuating shaft 34. Valve 42 is configured to assume (a) the open state when seal 54 is disposed at one or more first axial positions 56A with respect to proximal tube 52 (one such first axial position is shown in
For some applications, seal 54, actuating shaft 34, and proximal tube 52 are arranged such that seal 54 blocks fluid flow out of a distal end 58 of proximal tube 52, at least when seal 54 is disposed at the one or more first axial positions 56A with respect to proximal tube 52, such as shown in
For some applications, a wall of proximal tube 52 is shaped so as to define one or more tabs 60 through the wall. The one or more tabs 60 are biased to flex radially inward. When valve 42 is in the open state, as shown in
For some applications, the external surface of actuating shaft 34 is shaped so as to define one or more protrusions 66 around at least a portion of (e.g., entirely around) actuating shaft 34. Proximal ends 62 of the one or more tabs 60 are shaped so as to prevent distal movement of the one or more protrusions 66 when the one or more protrusions 66 are disposed proximal to the proximal ends 62 of the one or more tabs 60, such as shown in
For some applications, occlusion device 10 further comprises a proximal LAA-orifice cover 70, which:
This indirect connection of proximal LAA-orifice cover 70 to balloon 30 generally prevents an anodic reaction between the typically super-elastic (e.g., Nitinol) material of frame 72 of proximal LAA-orifice cover 70 and the typically plastically deformable (e.g., stainless steel) material of struts 80, described hereinbelow. Such a reaction might have occurred if the two elements were instead welded or otherwise bonded together in contact with each other. (Connection of the elements via an independent and passive element, such as an internal tube or shaft, also does not cause such a reaction.) Alternatively, proximal LAA-orifice cover 70 is directly connected to balloon 30, such as if frame 72 comprises a different plastically-deformable material, such as titanium.
For some applications, occlusion device 10 further comprises orifice-support stent 290, described hereinbelow with reference to
For some applications, actuating shaft 34 is shaped so as to define a guidewire lumen 76 for slidingly receiving therein a guidewire and/or passage of liquid injected under pressure, such as contrast media injected from the proximal handle of the delivery tool to the distal end of the occlusion device. Alternatively, for other applications, actuating shaft 34 is not shaped so as to define a guidewire lumen.
For some applications, compliant balloon 30 comprises a compliant material selected from the group consisting of: polycaprolactone (PCL), polyglycolic acid (PGA), polylactic acid (PLA), and polydioxanone (PDO or PDS), silicone, polyurethane, polytetrafluoroethylene (PTFE), polymethylmethacrylate, polyether ether ketone (PEEK), polyvinyl chloride, polyethylene terephthalate, nylon, polyamide, polyamide, and polyether block amide (PEBA).
For some applications, balloon 30 has an average wall thickness of between 100 and 5000 microns. Alternatively or additionally, for some applications, balloon 30 has, at a thinnest portion of a wall of balloon 30, a thinnest wall thickness of between 20 and 500 microns.
For some applications, occlusion device 10 further comprises connecting struts 80 fixed to distal end portion 36 of balloon 30 and to proximal end portion 38 of balloon 30. Struts 80 may be disposed inside balloon 30, outside balloon 30, or some inside and some outside balloon 30. For some applications, struts 80 are arranged as a frame. For some applications, struts 80 are arranged in a cage-like arrangement. Typically, struts 80 comprise a plastically-deformable material, such as stainless steel or titanium. Typically, struts 80 help shape balloon 30 as the balloon chamber is inflated and/or the balloon is shortened.
Typically, occlusion device 10 is configured such that inflation of balloon chamber 32 plastically deforms connecting struts 80. For some applications, occlusion device 10 is configured such that shortening of balloon 30 plastically deforms connecting struts 80.
For some applications, struts 80 are configured such that inflation of balloon chamber 32 primarily causes radial deformation of struts 80, rather than deformation of the struts in a distal or proximal direction. To this end, first lateral portions 81A of struts 80 arranged along a lateral surface of balloon 30 may be more compliant than second end portions 81B of struts 80 arranged on a distal surface of balloon 30 and/or on a proximal surface of balloon 30. For example, first lateral portions 81A may be thinner than second end portions 81B, as shown in
Reference is now made to
Reference is also made to
For some applications, occlusion device 10 comprises a proximal connector 84 that is configured to releasably connect occlusion device 10 to a correspondingly configured distal connector 86 of delivery system 20.
For some applications, distal connector 86 comprises one or more legs that engage one or more respective coupling sites (e.g., slots) of proximal connector 84, such as perhaps best seen in
Alternatively, proximal connector 84 is shaped so as to define a thread (configuration not shown).
For some applications, delivery system 20 comprises an implant catheter 88 that is connected to an operating handle (not shown). Implant catheter 88 comprises (a) a longitudinal passageway for a guidewire, (b) distal connector 86 for releasably connecting implant catheter 88 to correspondingly configured proximal connector 84 of occlusion device 10, and (c) an inflation tube channel releasably connectable to fluid flow path 44 of occlusion device 10. The longitudinal passageway may alternatively or additionally be used to inject contrast media from the handle to a distal opening of the inflation tube channel distally to the balloon.
Typically, a healthcare worker places the distal end of occlusion device 10 into the LAA, using delivery system navigation.
As shown in
For some applications, struts 80 are shaped so as to define a plurality of spikes 89 that are initially generally axially oriented, as shown in
Reference is now made to
For some applications, proximal LAA-orifice cover 70 is asymmetric about proximal tube 52, e.g., elliptical or with a radius greater in one direction than in the perpendicular direction.
For some applications, proximal LAA-orifice cover 70 is configured to have an adjustable greatest dimension measured perpendicular to proximal tube 52. For example, rotation of a proximal LAA-orifice cover 70 adjustment mechanism may adjust the greatest dimension.
For some applications, covering 74 of proximal LAA-orifice cover 70 is blood-permeable, so as to serve as filter for the passage of blood in and out of the LAA. For other applications, covering 74 is not blood-permeable, so as to create a secondary sealing of the LAA in addition to the sealing provided by balloon 30.
For some applications, proximal LAA-orifice cover 70 is bioresorbable and/or drug-eluting.
Reference is now made to
Reference is also made to
For some applications, occlusion device 110 comprises:
Occlusion device 110 is shaped so as to define a fluid flow path 144 having one or more fluid-flow-path openings 145 to balloon chamber 132. Typically, occlusion device 110 is configured such that fluid flow path 144 is coupled in fluid communication with delivery system 120 when occlusion device 110 is releasably connected to delivery system 120.
For example, elastomer sleeve 143 may comprise silicone.
Elastomer sleeve 143 is configured to have a resting state in which the sleeve covers and seals the one or more fluid-flow-path openings 145, such that valve 142 is in a closed state, as shown in
Delivery system 120 is configured to be releasably connected to occlusion device 110. Delivery system 120 comprises a valve-opening prop 147, which is configured:
This configuration enables separate control of shortening of balloon 130 and closing of valve 142. Alternatively, valve-opening prop 147 (e.g., tubular portion 151 thereof, described below) is fixed to pull shaft 46.
For some applications, valve-opening prop 147 comprises one or more tabs 149 that extend radially outward from an axis of elastomer sleeve 143, so as to prop open elastomer sleeve 143.
For some applications, valve-opening prop 147 is configured such that axial sliding thereof with respect to elastomer sleeve 143 (e.g., in a proximal direction) transitions valve-opening prop 147 from the propping position to the non-propping position, as shown in the transition between
For some applications, occlusion device 110 further comprises a proximal tube 152, which is axially fixed with respect to proximal end portion 138 of balloon 130. For some applications, actuating shaft 134 is slidably disposed partially within proximal tube 152.
For some applications, a seal, such as an O-ring (as shown), is provided, and friction between the seal and the inner surface of a proximal tube 152 increases structural stability. Alternatively or additionally, the O-ring, upon completion of the shortening of the balloon, is disposed proximal to the one or more fluid-flow-path openings 145 and blocks additional fluid from passing through the one or more fluid-flow-path openings 145 and elastomer sleeve 143.
For some applications, valve-opening prop 147 comprises a tubular portion 151, which is disposed at least partially within proximal tube 152. For some of these applications, valve-opening prop 147 comprises the one or more tabs 149, which extend (a) axially away from tubular portion 151 (e.g., in a distal direction) and (b) radially outward from proximal tube 152, so as to prop open elastomer sleeve 143. For some applications, the one or more tabs 149 pass through at least a portion of the one or more fluid-flow-path openings 145 when valve-opening prop 147 is in the propping position, such as shown in
For some applications, occlusion device 110 further comprises proximal LAA-orifice cover 70, which is fixed to proximal tube 152 radially surrounding proximal tube 152. Proximal LAA-orifice cover 70 may implement any of the techniques described hereinabove and/or hereinbelow. For some of these applications, occlusion device 110 further comprises an orifice-support stent 290, described hereinbelow with reference to
For some applications, occlusion device 110 further comprises a locking mechanism, which is configured to assume locked and unlocked states, and which is configured, when in the locked state, to maintain, between distal end portion 136 of balloon 130 and proximal end portion 138 of balloon 130, the distance set using actuating shaft 134. The locking mechanism may implement any of the locking mechanisms described herein, mutatis mutandis.
For some applications, actuating shaft 134 is shaped so as to define, at least in part, a distal tip 150 disposed at distal end portion 136 of balloon 130.
For some applications, occlusion device 110 further comprises connecting struts 180 fixed to distal end portion 136 of balloon 130 and to proximal end portion 138 of balloon 130. Typically, occlusion device 110 is configured such that inflation of balloon chamber 132 plastically deforms connecting struts 180. For some applications, occlusion device 110 is configured such that shortening of balloon 130 plastically deforms connecting struts 180.
For some applications, delivery system 120 further comprising implant catheter 88, such as described hereinabove with reference to
Reference is now made to
Occlusion device 410 comprises a valve 442, comprising elastomer sleeve 143 that surrounds a portion of actuating shaft 134. Elastomer sleeve 143 is configured to have a resting state in which the sleeve covers and seals the one or more fluid-flow-path openings 145, such that the valve is in a closed state (not shown in
Unlike delivery system 120 of occlusion device 110, the delivery system of the present configuration does not comprise valve-opening prop 147. Instead, the delivery system comprises one or more guidewires 447, which:
For some applications, the one or more guidewires 447 pass through at least a portion of the one or more fluid-flow-path openings 145 when the one or more guidewires are in the propping position.
Reference is now made to
Reference is also made to
Occlusion device 210 comprises:
Occlusion device 210 further comprises proximal LAA-orifice cover 70, which (a) is configured to assume a radially-compressed state and a radially-expanded state, (b) comprises frame 72 and covering 74 fixed to frame 72, and (c) when in the radially-expanded state, is generally orthogonal to actuating shaft 234 and has a greatest dimension, measured perpendicular to actuating shaft 234, of at least 10 mm (e.g., at least 20 mm), no more than 50 mm (e.g., no more than 30 mm), and/or between 10 and 50 mm (e.g., between 20 and 30 mm).
Occlusion device 210 still further comprises an orifice-support stent 290, which is configured to enhance support at the orifice of the LAA. Orifice-support stent 290 is configured to be positioned at least partially within the LAA, such as entirely within the LAA. Orifice-support stent 290 is:
As used in the present application, including in the claims and the Inventive Concepts, the phrase “generally cylindrical” is not limited to generally circularly cylindrical, and also includes within its scope other generally cylindrical shapes, such as generally elliptically cylindrical.
For some applications, orifice-support stent 290, when in the radially-expanded state, has (i) a greatest dimension, measured perpendicular to actuating shaft 234, of at least 8 mm, no more than 50 mm, and/or between 8 and 50 mm, and/or (ii) an axial length of at least 4 mm (e.g. at least 5 mm), no more than 30 mm, and/or between 4 and 30 mm.
For some applications, orifice-support stent 290 is not fixed to balloon 230, such that a shape of balloon 230 can change independently of a shape of orifice-support stent 290. Alternatively or additionally, lack of direct physical contact between orifice-support stent 290 and connecting struts 280 of occlusion device 210 prevents an anodic reaction between the typically super-elastic (e.g., Nitinol) material of struts 280 and the typically plastically deformable (e.g., stainless steel) material of orifice-support stent 290. Such a reaction might have occurred if the two elements were instead welded or otherwise bonded together in contact with each other. (Connection of the elements via an independent and passive element, such as an internal tube or shaft, also does not cause such a reaction.)
For some applications, orifice-support stent 290 comprises a super-elastic or plastically-deformable metal.
Typically, occlusion device 210 is configured such that inflation of balloon chamber 232 transitions orifice-support stent 290 from its radially-compressed state to its radially-expanded state. For some applications, because orifice-support stent 290 comprises a super-elastic metal, such as Nitinol, the stent, when crimped, will have a minimum diameter given by the thickness of its wall struts. When released, the stent tends to transition to its released diameter, which is higher than the crimped diameter. In configurations in which balloon 230 is inflated within the stent, the stent will over-stretch, and its diameter will be greater than its released diameter, to an extent that depends upon the design and ability of over-dilatation of the stent struts.
For some applications, occlusion device 210 further comprises a proximal tube 252, which is axially fixed with respect to proximal end portion 238 of balloon 230. For these applications, proximal LAA-orifice cover 70 is fixed to proximal tube 252 radially surrounding proximal tube 252, and is indirectly connected to balloon 230 via proximal tube 252 and is not directly connected to balloon 230.
Reference is now made to
Reference is also made to
Occlusion device 310 comprises:
Spring 353 is (a) disposed at least partially within balloon chamber 232, (b) connected (directly or indirectly, such as via a tube) to a distal end portion 336 of balloon 330 and proximal tube 352, and (c) has a relaxed length, as shown in
Delivery system 320 is configured to be releasably connected to occlusion device 310. Delivery system 320 comprises a stylet 355, which is removably disposed through proximal tube 352 and within spring 353. Occlusion device 310 is configured such that a degree of distal advancement of stylet 355 within spring 353 sets a tensed length of spring 353, which in turn sets a tensed distance between distal and proximal end portions 336 and 338 of balloon 330, the tensed distance greater than the relaxed distance. One possible tensed distance is shown in
Typically, during deployment of occlusion device 310 in the LAA, occlusion device 310 is advanced into the LAA with spring 353 in the elongated tensed state. Balloon chamber 332 is typically inflated while spring 353 is in the elongated tensed state, such as shown in
For some applications, a distal end portion of stylet 355 is releasably connected to an occlusion-device connector 357 of occlusion device 310, which is connected to distal end portion 336 of balloon 330. (Even though stylet 355 would generally remain in place even if not connected to occlusion device 310, if not thus connected stylet 355 might become disengaged from the center of spring 353 and become entangled with spring 353 during maneuvering of occlusion device 310 and inflation of balloon 330 during deployment.) For these applications, stylet 355 is disconnected from occlusion-device connector 357 after spring 353 has been allowed to shorten. For example, the end portion of stylet 355 and occlusion-device connector 357 may define respective threads.
Optionally, stylet 355 is flexible, e.g., highly flexible, to accommodate variations in LAA anatomy, including curvature of the LAA.
Reference is now made to
Occlusion device 510 comprises connecting struts 580 fixed to distal end portion 36 of balloon 30 and to proximal end portion 38 of balloon 30. Struts 580 may implement any of the features of struts 80, described hereinabove, mutatis mutandis. First lateral portions 581A of struts 580 are arranged along a lateral surface of balloon 30. Second distal-end portions 581B of struts 580 are arranged on a distal surface of balloon 30. Third proximal-end portions 581C of struts 580 are arranged on a proximal surface of balloon 30. Typically, second distal-end portions 581B and third proximal-end portions 581C are generally straight. Typically, first lateral portions 581A are oriented parallel to a central longitudinal axis of occlusion device 510.
For some applications, distal interface portions 583A of struts 580 join first lateral portions 581A and second distal-end portions 581B, respectively, and/or proximal interface portions 583B join first lateral portions 581A and third proximal-end portions 581C, respectively. Occlusion device 510 is configured such that upon inflation of balloon chamber 32, distal interface portions 583A and proximal interface portions 583B are curved, such as shown in
For some applications, distal end portions 585A of struts 580 join second distal-end portions 581B of struts 580 to distal end portion 36 of balloon 30, respectively, and/or proximal end portions 585B of struts 580 join third proximal-end portions 581C of struts 580 to proximal end portion 38 of balloon 30, respectively. Occlusion device 510 is configured such that upon inflation of balloon chamber 32, distal end portions 585A and proximal end portions 585B are curved. (
For some applications, struts 580 are shaped so as to define a plurality of spikes 589 that extend from outer ends 599 (labeled in
For some applications, distal interface portions 583A are shaped so as to define respective pairs of parallel serpentine (e.g., sinusoidal) struts 591A and 591B that define respective narrow elongate gaps 593 therebetween. When spikes 589 are initially generally axially oriented, as shown in
For some applications, connecting struts 580 further include closed stent cells 587 that connect adjacent pairs of first lateral portions 581A. Optionally, two or more closed stent cells 587 arranged in series connect the adjacent pairs of first lateral portions 581A (in the figures, exactly two closed stent cells 587 arranged in series are shown connecting the adjacent pairs of first lateral portions 581A); typically, no more than four closed stent cells 587 arranged in series, such as exactly two or three closed stent cells 587 arranged in series. These connections by closed stent cells 587 may help laterally stabilize first lateral portions 581A upon inflation of balloon chamber 32, and may help constrain the shape of balloon 30 upon inflation of balloon chamber 32, by helping limit radial expansion of the balloon out of the stent struts. These connections by closed stent cells 587 may alternatively or additionally stabilize the implantation of occlusion device 510 by friction, by providing a sufficiently large contract surface with the walls of the LAA. Optionally, a single series of two or more closed stent cells 587 connect adjacent pairs of first lateral portions 581A, as shown; alternatively, two or more series (e.g., exactly two series) of two or more closed stent cells 587 connect adjacent pairs of first lateral portions 581A (configuration not shown).
Typically, an average width of the struts of first lateral portions 581A equals at least 200% of an average width of the struts of closed stent cells 587, such as at least 250%, 300%, or 400%. As mentioned above, typically first lateral portions 581A are oriented parallel to a central longitudinal axis of occlusion device 510. The struts of closed stent cells 587 may have these thinner widths in order to allow expansion of the closed stent cells with the expansion of the balloon.
For some applications, closed stent cells 587 are shaped as respective rhombuses. Rhombuses can be radially compressed for delivery such that they predictably expand symmetrically, unlike many other stent shapes that tend to expand asymmetrically, such as S-shapes and serpentine shapes. Rhombuses also generally return to their original shape when plastically expanded for implantation after being plastically radially compressed for delivery. For some applications, the rhombuses may be shaped as squares and/or diamonds at certain levels of radial compression and expansion.
In an embodiment, the techniques and apparatus described herein are combined with techniques and apparatus described in one or more of the following patent applications, which are assigned to the assignee of the present application and are incorporated herein by reference:
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
The present application is the U.S. national stage of International Application PCT/IL2020/051041, filed Sep. 24, 2020, which published as PCT Publication WO 2021/059273 and which claims priority from U.S. Provisional Application 62/906,393, filed Sep. 26, 2019, which is assigned to the assignee of the present application and incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IL2020/051041 | 9/24/2020 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2021/059273 | 4/1/2021 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3834394 | Hunter et al. | Sep 1974 | A |
| 4686962 | Haber | Aug 1987 | A |
| 4802479 | Haber et al. | Feb 1989 | A |
| 5411475 | Atala et al. | May 1995 | A |
| 5499995 | Teirstein | Mar 1996 | A |
| 5795325 | Valley et al. | Aug 1998 | A |
| 5830228 | Knapp et al. | Nov 1998 | A |
| 5853422 | Huebsch et al. | Dec 1998 | A |
| 6117159 | Huebsch et al. | Sep 2000 | A |
| 6174322 | Schneidt | Jan 2001 | B1 |
| 6231561 | Frazier et al. | May 2001 | B1 |
| 6267747 | Samson et al. | Jul 2001 | B1 |
| 6290674 | Roue et al. | Sep 2001 | B1 |
| 6328727 | Frazier et al. | Dec 2001 | B1 |
| 6334864 | Amplatz et al. | Jan 2002 | B1 |
| 6419669 | Frazier et al. | Jul 2002 | B1 |
| 6440097 | Kupiecki | Aug 2002 | B1 |
| 6468301 | Amplatz et al. | Oct 2002 | B1 |
| 6468303 | Amplatz et al. | Oct 2002 | B1 |
| 6488689 | Kaplan et al. | Dec 2002 | B1 |
| 6537300 | Girton | Mar 2003 | B2 |
| 6544268 | Lazarus | Apr 2003 | B1 |
| 6551303 | Van Tassel et al. | Apr 2003 | B1 |
| 6638257 | Amplatz | Oct 2003 | B2 |
| 6652555 | VanTassel et al. | Nov 2003 | B1 |
| 6652556 | VanTassel et al. | Nov 2003 | B1 |
| 6656488 | Yi et al. | Dec 2003 | B2 |
| 6692491 | Phan | Feb 2004 | B1 |
| 6926712 | Phan | Aug 2005 | B2 |
| 6932816 | Phan | Aug 2005 | B2 |
| 6941169 | Pappu | Sep 2005 | B2 |
| 6942661 | Swanson | Sep 2005 | B2 |
| 6942681 | Johnson | Sep 2005 | B2 |
| 6964669 | Knapp et al. | Nov 2005 | B1 |
| 6970742 | Mann et al. | Nov 2005 | B2 |
| 6994092 | Van Der et al. | Feb 2006 | B2 |
| 7011671 | Welch | Mar 2006 | B2 |
| 7044134 | Khairkhahan et al. | May 2006 | B2 |
| 7056294 | Khairkhahan et al. | Jun 2006 | B2 |
| 7169164 | Borillo et al. | Jan 2007 | B2 |
| 7211048 | Najafi et al. | May 2007 | B1 |
| 7293562 | Malecki et al. | Nov 2007 | B2 |
| 7338514 | Wahr et al. | Mar 2008 | B2 |
| 7374560 | Ressemann et al. | May 2008 | B2 |
| 7470282 | Shelso | Dec 2008 | B2 |
| 7473271 | Gunderson | Jan 2009 | B2 |
| 7483743 | Mann et al. | Jan 2009 | B2 |
| 7549988 | Eberl et al. | Jun 2009 | B2 |
| 7597704 | Frazier et al. | Oct 2009 | B2 |
| 7604612 | Ressemann et al. | Oct 2009 | B2 |
| 7615010 | Najafi et al. | Nov 2009 | B1 |
| 7654978 | Wahr et al. | Feb 2010 | B2 |
| 7713282 | Frazier et al. | May 2010 | B2 |
| 7722641 | Van Der Burg et al. | May 2010 | B2 |
| 7735493 | Van Der Burg et al. | Jun 2010 | B2 |
| 7740627 | Gammie et al. | Jun 2010 | B2 |
| 7749157 | Bertolero | Jul 2010 | B2 |
| 7824341 | Krishnan | Nov 2010 | B2 |
| 7828818 | Zang et al. | Nov 2010 | B2 |
| 7837619 | Sogard et al. | Nov 2010 | B2 |
| 7846168 | Liddicoat et al. | Dec 2010 | B2 |
| 7846175 | Bonnette et al. | Dec 2010 | B2 |
| 7857811 | Vaska et al. | Dec 2010 | B2 |
| 7892228 | Landis et al. | Feb 2011 | B2 |
| 7918865 | Liddicoat et al. | Apr 2011 | B2 |
| 7972359 | Kreidler | Jul 2011 | B2 |
| 7976564 | Blaeser et al. | Jul 2011 | B2 |
| 7998095 | McAuley | Aug 2011 | B2 |
| 7998138 | McAuley | Aug 2011 | B2 |
| 8002771 | Cox et al. | Aug 2011 | B2 |
| 8034061 | Amplatz et al. | Oct 2011 | B2 |
| 8043258 | Ostroot | Oct 2011 | B2 |
| 8048147 | Adams | Nov 2011 | B2 |
| 8052715 | Quinn et al. | Nov 2011 | B2 |
| 8057530 | Kusleika et al. | Nov 2011 | B2 |
| 8080032 | Van Der Burg et al. | Dec 2011 | B2 |
| 8097015 | Devellian | Jan 2012 | B2 |
| 8100938 | Figulla et al. | Jan 2012 | B2 |
| 8108069 | Stahler et al. | Jan 2012 | B2 |
| 8114123 | Brenzel et al. | Feb 2012 | B2 |
| 8133221 | Malecki et al. | Mar 2012 | B2 |
| 8142470 | Quinn et al. | Mar 2012 | B2 |
| 8148470 | Holtcamp et al. | Apr 2012 | B1 |
| 8162974 | Eskuri et al. | Apr 2012 | B2 |
| 8163004 | Amplatz et al. | Apr 2012 | B2 |
| 8167894 | Miles et al. | May 2012 | B2 |
| 8167905 | Michler et al. | May 2012 | B2 |
| 8197527 | Borillo et al. | Jun 2012 | B2 |
| 8204605 | Hastings et al. | Jun 2012 | B2 |
| 8211096 | Pless et al. | Jul 2012 | B2 |
| 8221348 | Hackett et al. | Jul 2012 | B2 |
| 8221405 | Whisenant et al. | Jul 2012 | B2 |
| 8235885 | Whisenant et al. | Aug 2012 | B2 |
| 8235988 | Davis et al. | Aug 2012 | B2 |
| 8252051 | Chau et al. | Aug 2012 | B2 |
| 8257724 | Cromack et al. | Sep 2012 | B2 |
| 8257725 | Cromack et al. | Sep 2012 | B2 |
| 8308798 | Pintor et al. | Nov 2012 | B2 |
| 8313505 | Amplatz et al. | Nov 2012 | B2 |
| 8361138 | Adams | Jan 2013 | B2 |
| 8366743 | Zeng et al. | Feb 2013 | B2 |
| 8372112 | Christianson et al. | Feb 2013 | B2 |
| 8398670 | Amplatz et al. | Mar 2013 | B2 |
| 8402974 | Davis et al. | Mar 2013 | B2 |
| 8408214 | Spenser | Apr 2013 | B2 |
| 8409219 | Kelley et al. | Apr 2013 | B2 |
| 8463359 | Saadat et al. | Jun 2013 | B2 |
| 8480708 | Kassab et al. | Jul 2013 | B2 |
| 8491649 | Mach | Jul 2013 | B2 |
| 8511214 | Gries | Aug 2013 | B2 |
| 8523897 | Van Der Burg et al. | Sep 2013 | B2 |
| 8523940 | Richardson et al. | Sep 2013 | B2 |
| 8529597 | Linder et al. | Sep 2013 | B2 |
| 8540616 | Whisenant et al. | Sep 2013 | B2 |
| 8545491 | Abboud et al. | Oct 2013 | B2 |
| 8550982 | Eby | Oct 2013 | B2 |
| 8568474 | Yeung et al. | Oct 2013 | B2 |
| 8574264 | Blaeser et al. | Nov 2013 | B2 |
| 8613765 | Bonhoeffer et al. | Dec 2013 | B2 |
| 8617145 | Longoria | Dec 2013 | B2 |
| 8621975 | Russo et al. | Jan 2014 | B2 |
| 8636764 | Miles et al. | Jan 2014 | B2 |
| 8647361 | Borillo et al. | Feb 2014 | B2 |
| 8647367 | Kassab et al. | Feb 2014 | B2 |
| 8652201 | Oberti et al. | Feb 2014 | B2 |
| 8663245 | Francischelli et al. | Mar 2014 | B2 |
| 8673001 | Cartledge et al. | Mar 2014 | B2 |
| 8690911 | Miles et al. | Apr 2014 | B2 |
| 8696742 | Pintor et al. | Apr 2014 | B2 |
| 8709007 | Vaska | Apr 2014 | B2 |
| 8715270 | Weitzner et al. | May 2014 | B2 |
| 8721636 | Vaska et al. | May 2014 | B2 |
| 8740934 | McGuckin, Jr. | Jun 2014 | B2 |
| 8747297 | Miyoshi et al. | Jun 2014 | B2 |
| 8747453 | Amplatz et al. | Jun 2014 | B2 |
| 8747462 | Hill et al. | Jun 2014 | B2 |
| 8758294 | Kim et al. | Jun 2014 | B2 |
| 8758372 | Cartledge et al. | Jun 2014 | B2 |
| 8758389 | Glimsdale | Jun 2014 | B2 |
| 8764787 | Ren | Jul 2014 | B2 |
| 8764793 | Lee | Jul 2014 | B2 |
| 8771297 | Miller et al. | Jul 2014 | B2 |
| 8777974 | Amplatz et al. | Jul 2014 | B2 |
| 8778008 | Amplatz et al. | Jul 2014 | B2 |
| 8784469 | Kassab | Jul 2014 | B2 |
| 8795310 | Fung et al. | Aug 2014 | B2 |
| 8795328 | Miles et al. | Aug 2014 | B2 |
| 8801706 | Rothstein et al. | Aug 2014 | B2 |
| 8801746 | Kreidler et al. | Aug 2014 | B1 |
| 8808371 | Cartledge | Aug 2014 | B2 |
| 8814778 | Kiser et al. | Aug 2014 | B2 |
| D713527 | Heipl | Sep 2014 | S |
| 8821529 | Kariniemi et al. | Sep 2014 | B2 |
| 8834519 | Van Der Burg et al. | Sep 2014 | B2 |
| 8840641 | Miles et al. | Sep 2014 | B2 |
| 8840655 | Edmiston et al. | Sep 2014 | B2 |
| 8845711 | Miles et al. | Sep 2014 | B2 |
| 8864809 | Miles et al. | Oct 2014 | B2 |
| 8864823 | Cartledge et al. | Oct 2014 | B2 |
| 8876776 | Kassab et al. | Nov 2014 | B2 |
| 8880185 | Hastings et al. | Nov 2014 | B2 |
| 8882830 | Cartledge et al. | Nov 2014 | B2 |
| 8900287 | Amplatz et al. | Dec 2014 | B2 |
| 8915958 | Braido | Dec 2014 | B2 |
| 8940015 | Kariniemi | Jan 2015 | B2 |
| 8951251 | Willard | Feb 2015 | B2 |
| 8956304 | Schecter | Feb 2015 | B2 |
| 8974451 | Smith | Mar 2015 | B2 |
| 8979941 | Davis et al. | Mar 2015 | B2 |
| 8986375 | Garde et al. | Mar 2015 | B2 |
| D727500 | Heipl | Apr 2015 | S |
| D727501 | Heipl | Apr 2015 | S |
| D728102 | Heipl | Apr 2015 | S |
| 9011551 | Oral et al. | Apr 2015 | B2 |
| 9017375 | Thommen | Apr 2015 | B2 |
| 9023034 | Jenson et al. | May 2015 | B2 |
| 9028485 | Edmunds et al. | May 2015 | B2 |
| 9034006 | Quinn et al. | May 2015 | B2 |
| 9039724 | Amplatz et al. | May 2015 | B2 |
| 9039752 | Russo et al. | May 2015 | B2 |
| 9050106 | Hill et al. | Jun 2015 | B2 |
| 9055933 | Escobar et al. | Jun 2015 | B2 |
| 9055959 | Vaska et al. | Jun 2015 | B2 |
| 9060761 | Hastings et al. | Jun 2015 | B2 |
| 9066710 | Dale et al. | Jun 2015 | B2 |
| 9066826 | Heidner et al. | Jun 2015 | B2 |
| 9072602 | Glozman et al. | Jul 2015 | B2 |
| 9072604 | Melnick et al. | Jul 2015 | B1 |
| 9079000 | Hanson et al. | Jul 2015 | B2 |
| 9084589 | Moszner | Jul 2015 | B2 |
| 9084609 | Smith | Jul 2015 | B2 |
| 9084621 | Weitzner et al. | Jul 2015 | B2 |
| 9089350 | Willard | Jul 2015 | B2 |
| 9089414 | Zimmerman et al. | Jul 2015 | B2 |
| 9107750 | Cartledge et al. | Aug 2015 | B2 |
| 9113890 | Dasnurkar et al. | Aug 2015 | B2 |
| 9119600 | Richardson et al. | Sep 2015 | B2 |
| 9119632 | Jenson et al. | Sep 2015 | B2 |
| 9125653 | Kovach | Sep 2015 | B2 |
| 9131932 | Tegels | Sep 2015 | B2 |
| 9132007 | Menk et al. | Sep 2015 | B2 |
| 9138208 | Linder et al. | Sep 2015 | B2 |
| 9144431 | Friedman et al. | Sep 2015 | B2 |
| 9144663 | Ahlberg et al. | Sep 2015 | B2 |
| 9155589 | Jenson | Oct 2015 | B2 |
| 9161758 | Figulla et al. | Oct 2015 | B2 |
| 9162046 | Hill et al. | Oct 2015 | B2 |
| 9173696 | Schauer et al. | Nov 2015 | B2 |
| 9186174 | Krishnan | Nov 2015 | B2 |
| 9186209 | Weber et al. | Nov 2015 | B2 |
| 9186210 | Jenson | Nov 2015 | B2 |
| 9186211 | Mathur | Nov 2015 | B2 |
| 9192435 | Jenson | Nov 2015 | B2 |
| 9192790 | Hastings et al. | Nov 2015 | B2 |
| 9198683 | Friedman et al. | Dec 2015 | B2 |
| 9216014 | Devellian et al. | Dec 2015 | B2 |
| 9220402 | Rothe et al. | Dec 2015 | B2 |
| 9220487 | Davis et al. | Dec 2015 | B2 |
| 9220558 | Willard | Dec 2015 | B2 |
| 9220561 | Crow et al. | Dec 2015 | B2 |
| 9226838 | Wang et al. | Jan 2016 | B2 |
| 9232992 | Heidner et al. | Jan 2016 | B2 |
| 9241792 | Benichou et al. | Jan 2016 | B2 |
| 9254141 | Morris et al. | Feb 2016 | B2 |
| 9254192 | Lutter et al. | Feb 2016 | B2 |
| 9271736 | Heipl | Mar 2016 | B2 |
| 9277905 | Cully et al. | Mar 2016 | B2 |
| 9277915 | Belson et al. | Mar 2016 | B2 |
| 9289266 | Weitzner et al. | Mar 2016 | B2 |
| 9290612 | Martin et al. | Mar 2016 | B2 |
| 9295472 | Ottma | Mar 2016 | B2 |
| 9295484 | Solem | Mar 2016 | B2 |
| 9297845 | Mathur | Mar 2016 | B2 |
| 9301838 | Kapadia | Apr 2016 | B2 |
| 9307999 | Li et al. | Apr 2016 | B2 |
| 9320525 | Khieu et al. | Apr 2016 | B2 |
| 9326751 | Hastings | May 2016 | B2 |
| 9326852 | Spenser | May 2016 | B2 |
| 9333073 | Quadri et al. | May 2016 | B2 |
| 9339274 | Dakin | May 2016 | B2 |
| 9345462 | Weitzner et al. | May 2016 | B2 |
| 9351716 | Miles et al. | May 2016 | B2 |
| 9358365 | Smith et al. | Jun 2016 | B2 |
| 9364284 | Groff et al. | Jun 2016 | B2 |
| 9370418 | Pintor et al. | Jun 2016 | B2 |
| 9375209 | Akpinar | Jun 2016 | B2 |
| 9375218 | Wheeler et al. | Jun 2016 | B2 |
| 9398951 | Alkhatib et al. | Jul 2016 | B2 |
| 9408608 | Clark, III et al. | Aug 2016 | B2 |
| 9408661 | Haverkost | Aug 2016 | B2 |
| 9408951 | Larsen et al. | Aug 2016 | B2 |
| 9414842 | Glimsdale et al. | Aug 2016 | B2 |
| 9420955 | Weber | Aug 2016 | B2 |
| 9421071 | Smith et al. | Aug 2016 | B2 |
| 9427215 | Cartledge et al. | Aug 2016 | B2 |
| 9427235 | Krishnan | Aug 2016 | B2 |
| 9427550 | Dakin et al. | Aug 2016 | B2 |
| 9433760 | Subramaniam et al. | Sep 2016 | B2 |
| 9445798 | Amplatz et al. | Sep 2016 | B2 |
| 9445799 | Amplatz et al. | Sep 2016 | B2 |
| 9456877 | Weitzner et al. | Oct 2016 | B2 |
| 9456897 | Krivoruchko et al. | Oct 2016 | B2 |
| 9463024 | Kiser et al. | Oct 2016 | B2 |
| 9463062 | Smith et al. | Oct 2016 | B2 |
| 9468437 | Michler et al. | Oct 2016 | B2 |
| 9474516 | Clark et al. | Oct 2016 | B2 |
| 9474598 | Gregg et al. | Oct 2016 | B2 |
| 9474599 | Keränen | Oct 2016 | B2 |
| 9492156 | Tegels | Nov 2016 | B2 |
| 9492276 | Lee et al. | Nov 2016 | B2 |
| 9492623 | Kapadia et al. | Nov 2016 | B2 |
| 9498206 | Fung et al. | Nov 2016 | B2 |
| 9498228 | Dale et al. | Nov 2016 | B2 |
| 9510811 | Akpinar | Dec 2016 | B2 |
| 9532772 | Moszner et al. | Jan 2017 | B2 |
| 9545306 | Tabor | Jan 2017 | B2 |
| 9572583 | Kauphusman et al. | Feb 2017 | B2 |
| 9579030 | Scheuermann et al. | Feb 2017 | B2 |
| 9579194 | Elizondo et al. | Feb 2017 | B2 |
| 9585643 | Terwey | Mar 2017 | B2 |
| 9585644 | Linder et al. | Mar 2017 | B2 |
| 9610082 | Morris et al. | Apr 2017 | B2 |
| 9622133 | Guvenc | Apr 2017 | B1 |
| 9636222 | Oslund | May 2017 | B2 |
| 9642706 | Eidenschink | May 2017 | B2 |
| 9649115 | Edmiston et al. | May 2017 | B2 |
| 9649156 | Jenson et al. | May 2017 | B2 |
| 9650730 | Heipl et al. | May 2017 | B2 |
| 9655606 | Le | May 2017 | B2 |
| 9662205 | Eidenschink | May 2017 | B2 |
| 9668811 | Sogard et al. | Jun 2017 | B2 |
| 9668856 | Para | Jun 2017 | B2 |
| 9668857 | Braido et al. | Jun 2017 | B2 |
| 9668858 | Morin et al. | Jun 2017 | B2 |
| 9675451 | Garde et al. | Jun 2017 | B2 |
| 9681861 | Heisel et al. | Jun 2017 | B2 |
| 9687166 | Subramaniam et al. | Jun 2017 | B2 |
| 9687341 | Alkhatib et al. | Jun 2017 | B2 |
| 9687585 | Bernasconi et al. | Jun 2017 | B2 |
| 9693781 | Miles et al. | Jul 2017 | B2 |
| 9693821 | Hanson et al. | Jul 2017 | B2 |
| 9694115 | Zhang et al. | Jul 2017 | B2 |
| 9700323 | Clark | Jul 2017 | B2 |
| 9707036 | Anderson et al. | Jul 2017 | B2 |
| 9713730 | Mathur et al. | Jul 2017 | B2 |
| 9717501 | Kauphusman et al. | Aug 2017 | B2 |
| 9730701 | Tischler et al. | Aug 2017 | B2 |
| 9737309 | Ad | Aug 2017 | B1 |
| 9750605 | Ganesan et al. | Sep 2017 | B2 |
| 9757230 | Fahim et al. | Sep 2017 | B2 |
| 9770606 | Pikus et al. | Sep 2017 | B2 |
| 9775533 | Ong et al. | Oct 2017 | B2 |
| 9789232 | Liu et al. | Oct 2017 | B2 |
| 9795387 | Miles et al. | Oct 2017 | B2 |
| 9795481 | Callas et al. | Oct 2017 | B2 |
| 9795765 | Romoscanu | Oct 2017 | B2 |
| 9808253 | Li et al. | Nov 2017 | B2 |
| 9808300 | Hastings et al. | Nov 2017 | B2 |
| 9808311 | Wang et al. | Nov 2017 | B2 |
| 9820851 | Braido | Nov 2017 | B2 |
| 9820852 | Braido et al. | Nov 2017 | B2 |
| 9827039 | Dandler et al. | Nov 2017 | B2 |
| 9833283 | Hanson et al. | Dec 2017 | B2 |
| 9839430 | Willems et al. | Dec 2017 | B2 |
| 9839431 | Meyer et al. | Dec 2017 | B2 |
| 9844453 | Stack et al. | Dec 2017 | B2 |
| 9848898 | Friedman et al. | Dec 2017 | B2 |
| 9848976 | Angel et al. | Dec 2017 | B2 |
| 9848981 | Suri et al. | Dec 2017 | B2 |
| 9863031 | Zhang et al. | Jan 2018 | B2 |
| 9867697 | Alkhatib et al. | Jan 2018 | B2 |
| 9877710 | Amplatz et al. | Jan 2018 | B2 |
| 9877726 | Liu et al. | Jan 2018 | B2 |
| 9878072 | Zhang et al. | Jan 2018 | B2 |
| 9883855 | Tegels et al. | Feb 2018 | B2 |
| 9883936 | Sutton et al. | Feb 2018 | B2 |
| 9888926 | Phan et al. | Feb 2018 | B2 |
| 9889004 | Braido | Feb 2018 | B2 |
| 9895194 | Anderson et al. | Feb 2018 | B2 |
| 9901443 | Morriss et al. | Feb 2018 | B2 |
| 9907609 | Cao et al. | Mar 2018 | B2 |
| 9913652 | Bridgeman et al. | Mar 2018 | B2 |
| 9913715 | Braido et al. | Mar 2018 | B2 |
| 9918707 | Zhuang | Mar 2018 | B2 |
| 9919080 | Chen et al. | Mar 2018 | B1 |
| 9925001 | Willard et al. | Mar 2018 | B2 |
| 9931204 | Rothstein et al. | Apr 2018 | B2 |
| 9936956 | Fung et al. | Apr 2018 | B2 |
| 9943315 | Kaplan et al. | Apr 2018 | B2 |
| 9943365 | Haverkost et al. | Apr 2018 | B2 |
| 9949825 | Braido et al. | Apr 2018 | B2 |
| 9955971 | Xu et al. | May 2018 | B2 |
| 9956033 | Squire et al. | May 2018 | B2 |
| 9962223 | Lindquist et al. | May 2018 | B2 |
| 9974649 | Racchini et al. | May 2018 | B2 |
| 9980818 | Chau et al. | May 2018 | B2 |
| 9993234 | Maslanka et al. | Jun 2018 | B2 |
| 10010402 | Wang et al. | Jul 2018 | B2 |
| 10013082 | Schecter | Jul 2018 | B2 |
| 10016200 | Tegels | Jul 2018 | B2 |
| 10022182 | Willard et al. | Jul 2018 | B2 |
| 10028746 | Prom | Jul 2018 | B2 |
| 10034748 | Tseng et al. | Jul 2018 | B2 |
| 10045784 | Friedman et al. | Aug 2018 | B2 |
| 10052168 | Krishnan | Aug 2018 | B2 |
| 10058348 | Morris et al. | Aug 2018 | B2 |
| 10058636 | Xie et al. | Aug 2018 | B2 |
| 10058639 | Zhang et al. | Aug 2018 | B2 |
| 10064612 | Malakan Rad et al. | Sep 2018 | B2 |
| 10064628 | Edmiston et al. | Sep 2018 | B2 |
| 10076330 | Sander et al. | Sep 2018 | B2 |
| 10076335 | Zaver et al. | Sep 2018 | B2 |
| 10085799 | Smith | Oct 2018 | B2 |
| 10098640 | Bertolero et al. | Oct 2018 | B2 |
| 10105219 | Kovach | Oct 2018 | B2 |
| 10117743 | Kumar et al. | Nov 2018 | B2 |
| 10130369 | Fung et al. | Nov 2018 | B2 |
| 10130467 | Braido et al. | Nov 2018 | B2 |
| 10143478 | Forbes | Dec 2018 | B2 |
| 10143551 | Braido et al. | Dec 2018 | B2 |
| 20030191516 | Weldon et al. | Oct 2003 | A1 |
| 20030220667 | Van Der Burg et al. | Nov 2003 | A1 |
| 20040098017 | Saab et al. | May 2004 | A1 |
| 20040254594 | Alfaro | Dec 2004 | A1 |
| 20050288706 | Widomski et al. | Dec 2005 | A1 |
| 20060004442 | Spenser et al. | Jan 2006 | A1 |
| 20060200191 | Zadno-azizi et al. | Sep 2006 | A1 |
| 20070135831 | Burnett | Jun 2007 | A1 |
| 20070225756 | Preinitz et al. | Sep 2007 | A1 |
| 20080071310 | Hoffman et al. | Mar 2008 | A1 |
| 20080103479 | Cheng et al. | May 2008 | A1 |
| 20100185233 | Thommen | Jul 2010 | A1 |
| 20110172697 | Jonsson | Jul 2011 | A1 |
| 20120078295 | Steiner et al. | Mar 2012 | A1 |
| 20120323270 | Lee | Dec 2012 | A1 |
| 20130030519 | Tran et al. | Jan 2013 | A1 |
| 20130211495 | Halden et al. | Aug 2013 | A1 |
| 20140100596 | Rudman et al. | Apr 2014 | A1 |
| 20140257457 | Glazier et al. | Sep 2014 | A1 |
| 20140277426 | Dakin et al. | Sep 2014 | A1 |
| 20160045165 | Braido et al. | Feb 2016 | A1 |
| 20180008248 | Rafiee et al. | Jan 2018 | A1 |
| 20180161039 | Harks | Jun 2018 | A1 |
| 20200054343 | Min | Feb 2020 | A1 |
| 20200107836 | O'halloran et al. | Apr 2020 | A1 |
| 20200275935 | Maisano et al. | Sep 2020 | A1 |
| 20210204961 | Maisano et al. | Jul 2021 | A1 |
| 20210386429 | Franano et al. | Dec 2021 | A1 |
| 20230146949 | Guidotti et al. | May 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 104905890 | Sep 2015 | CN |
| 106344082 | Jan 2017 | CN |
| 1651117 | Jan 2007 | EP |
| 1113751 | Mar 2007 | EP |
| 1154723 | Dec 2007 | EP |
| 1891902 | Feb 2008 | EP |
| 1788957 | Mar 2008 | EP |
| 1 974 685 | Oct 2008 | EP |
| 1881804 | Sep 2009 | EP |
| 1313406 | Jun 2010 | EP |
| 1123130 | Jul 2010 | EP |
| 1948030 | Jul 2010 | EP |
| 1441649 | Aug 2011 | EP |
| 1993621 | Aug 2011 | EP |
| 1842490 | Sep 2011 | EP |
| 2074953 | Jun 2012 | EP |
| 2019633 | Aug 2012 | EP |
| 2248471 | Oct 2012 | EP |
| 1575421 | Oct 2013 | EP |
| 2327429 | Sep 2014 | EP |
| 1761296 | Nov 2014 | EP |
| 1765225 | Sep 2015 | EP |
| 2630919 | Sep 2015 | EP |
| 2822656 | Oct 2016 | EP |
| 2872051 | Mar 2017 | EP |
| 2970572 | Apr 2017 | EP |
| 2779910 | May 2017 | EP |
| 2967852 | Jun 2017 | EP |
| 3037043 | Sep 2017 | EP |
| 2617386 | Oct 2017 | EP |
| 2819585 | Nov 2017 | EP |
| 3043746 | Nov 2017 | EP |
| 3183012 | Dec 2017 | EP |
| 1768604 | Jan 2018 | EP |
| 2967869 | Jan 2018 | EP |
| 3125780 | Jan 2018 | EP |
| 3044221 | Feb 2018 | EP |
| 2575678 | May 2018 | EP |
| 2833836 | May 2018 | EP |
| 2908744 | Aug 2018 | EP |
| 2918251 | Aug 2018 | EP |
| 3193791 | Aug 2018 | EP |
| 2753246 | Nov 2018 | EP |
| 3010446 | Dec 2018 | EP |
| 3 459 469 | Mar 2019 | EP |
| 3459469 | Mar 2019 | EP |
| 3 620 134 | Mar 2020 | EP |
| 95032018 | Nov 1995 | WO |
| 1999018886 | Apr 1999 | WO |
| 2000012169 | Mar 2000 | WO |
| 2005092204 | Oct 2005 | WO |
| 2013068466 | May 2013 | WO |
| 2014085590 | Jun 2014 | WO |
| 2016149653 | Sep 2016 | WO |
| 2017079234 | May 2017 | WO |
| 2017161283 | Sep 2017 | WO |
| 2019057950 | Mar 2019 | WO |
| 2020060587 | Mar 2020 | WO |
| 2021191833 | Sep 2021 | WO |
| Entry |
|---|
| A Notice of Allowance issued in U.S. Appl. No. 16/649,777, dated Jun. 24, 2022. |
| Translation of an Office Action issued in JP 516870/2020, dated Sep. 27, 2022. |
| Extended European Search issued in European Appl. No. 19862977.6, dated Dec. 15, 2022. |
| A First Examination Report in Indian Appl. No. 202117016867, dated Feb. 3, 2023. |
| Translation of an Office Action in Japanese Appl. No. 516654/2021, dated Feb. 14, 2023. |
| Translation of an Office Action in Chinese Appl. No. 201880061656.0, dated Feb. 23, 2023. |
| Translation of a Decision of Refusal in Japanese Appl. No. 516870/2020, dated Jul. 11, 2023. |
| Translation of an Office Action in Chinese Appl. No. 201880061656.0, dated Oct. 18, 2023. |
| An International Search Report and a Written Opinion both dated Dec. 4, 2018, which issued during the prosecution of Applicant's PCT/EP2018/075716. |
| An International Search Report and a Written Opinion both dated Jun. 18, 2019, which issued during the prosecution of Applicant's PCT/US2019/024065. |
| An International Search Report and a Written Opinion both dated Jul. 6, 2021, which issued duirng the prosecution of Applicant's PCT/IB2021/052474. |
| An International Search Report and a Written Opinion both dated Mar. 29, 2021, which issued during the prosecution of Applicant's PCT/IL2020/051041. |
| European Search Report dated Mar. 12, 2018 which issued during the prosecution of Applicant's European App No. 17192792.4. |
| An Office Action dated Mar. 7, 2022, which issued during the prosecution of Indian Patent Application No. 202017015683. |
| An Office Action dated Dec. 22, 2021, which issued during the prosecution of U.S. Appl. No. 16/649,777. |
| Number | Date | Country | |
|---|---|---|---|
| 20220370079 A1 | Nov 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62906393 | Sep 2019 | US |
